FDA Concept Paper: Drug Products That Present Demonstrable Difficulties for...
...In addition, careful control of the impurities and degradation products in the drug substance and drug formulation.....Metered dose inhalers are sophisticated drug delivery systems that require extensive.....In addition, careful control of the impurities and degradation products in the drug substance and other drug formulation..
http://www.fda.gov/cder/fdama/difconc.htm (score=100)

Guideline for Efficacy Evaluation of Canine/Feline Anthelmintics
...The recommended dose of the drug, as established in the Titration Trials, should be administered to.....Principals should be treated with the proposed dose level and formulation of the product as recommended.....A difference may be acceptable in the route of administration and/or formulation..
http://www.fda.gov/cvm/guidance/guideline36.html (score=77)

...Since the inactive components in the drug formulation may exceed 95 to 99 percent, an MDI used.....The guidance reflects the Agency's current recommendations regarding the integration of.....Department of Health and Human Services Food and Drug Administration Center for Drug..
http://www.fda.gov/cder/guidance/5308FNL.doc (score=50)

Guidance for Industry
...oral inhalation integrate a dose-counting device into the development of their MDI drug product.Dose.....A complicating,but necessary design feature of MDIs is that they contain more formulation.....metered dose are more clinically important for oral inhalation drug products than for the..
http://www.fda.gov/cder/guidance/5308FNL.pdf (score=50)

MDI and DPI Drug Products
...establish a set of criteria to which a drug substance or drug product should conform using.....an internal reservoir containing sufficient formulation for multiple doses that are.....also known as oral and nasal metered dose inhalers respectively or MDIs) and inhalation..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=36)

...So, it's both involved in formulation development to find out a proper formulation for that drug substance, as.....For the drug B and drug C, I will show one natural exposure dose-ranging study for B and for C, and then I'll also show a study.....If I give a greater dose or I see a greater amount delivered from one formulation versus..
http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3764t1.txt (score=35)

...So, it's both involved in formulation development to find out a proper formulation for that drug substance, as.....For the drug B and drug C, I will show one natural exposure dose-ranging study for B and for C, and then I'll also show a study.....If I give a greater dose or I see a greater amount delivered from one formulation versus..
http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3764t1.htm (score=34)

SLR052ap.whi.doc
...Estrogen administration should be guided by clinical response at the lowest dose for the.....Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers.....Premarin Vaginal Cream should be used at the lowest possible dose for your treatment and..
http://www.fda.gov/cder/foi/label/2004/020216s052lbl.pdf (score=32)

/a/content.17222
...If it is almost time for your next dose, skip the missed dose and go back to your normal.....Chloasma or melasma that may persist when drug is discontinued.Erythema multiforme.....after release from the drug formulation. The Premarin tablet releases conjugated estrogens..
http://www.fda.gov/cder/foi/label/2003/04782s129lbl.pdf (score=32)

/a/content.31515
...If it is almost time for your next dose, skip the missed dose and go back to your normal.....Chloasma or melasma that may persist when drug is discontinued.Erythema multiforme.....after release from the drug formulation. The Premarin tablet releases conjugated estrogens..
http://www.fda.gov/medwatch/SAFETY/2003/premarin_PI.pdf (score=32)

April 2000 Safety-Related Drug Labeling Changes
...To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 2 hours.....Therefore, if Agenerase is used in pregnant women, the Agenerase Capsules formulation.....The recommended daily dose of Agenerase Oral Solution of 22.5 mg/kg twice daily..
http://www.fda.gov/medwatch/safety/2000/apr00.htm (score=27)

Paxil CR
...of a course of drug therapy, or at the time of dose changes, either increases or decreases.Consideration should be given.....of the immediate-release formulation of 20 mg to 40 mg daily for the elderly and 20 mg to.....dose-related increase in the number of tumors in mice, there was no drug-related increase..
http://www.fda.gov/medwatch/SAFETY/2004/PaxilCR_PI.pdf (score=27)

þÿ
...elderly and nonelderly patients, at doses of the immediate-release formulation of 20 to 40.....was observed typically between 6 and 10 hours post-dose,reflecting a reduction in.....addition to controlling the rate of drug release in vivo,an enteric coat delays the start..
http://www.fda.gov/cder/foi/label/2002/20982lbl.pdf (score=26)

þÿ
...by analysis of such features as relationship to dose, relationship to drug concentration,disappearance on.....Relationships of antibody formation to underlying disease, concomitant medication, dose, duration,regimen, and.....drug effect, any dose-response or drug concentration-response relationship or relationship..
http://www.fda.gov/cder/guidance/4539E.pdf (score=26)

...Comparison of an Anti-Inflammatory Dose of Ibuprofen, An Analgesic Dose of Ibuprofen, and Acetaminophen in the Treatment.....For instance, ibuprofen in suspension formulation for adult use has not been marketed OTC.....Ibuprofen has been available as a prescription drug for the treatment of osteoarthritis..
http://www.fda.gov/OHRMS/DOCKETS/98fr/082102a.htm (score=26)

paxil.PDF
...elderly and nonelderly patients, at doses of the immediate-release formulation of 20 to 40.....was observed typically between 6 and 10 hours post-dose,reflecting a reduction in.....addition to controlling the rate of drug release in vivo,an enteric coat delays the start..
http://www.fda.gov/cder/foi/label/1999/20936lbl.pdf (score=26)

þÿ

http://www.fda.gov/cder/foi/label/2002/21360lbl.pdf (score=24)

Microsoft Word - 5341fnl.doc
...pharmacological effect or clinical benefit effect in relation to dose or drug concentration.The.....Exposure-response data are not likely to obviate the need for clinical data when.....situations, generally involving a very well-tolerated drug with little dose-related..
http://www.fda.gov/cder/guidance/5341fnl.pdf (score=24)

...So, the bottom line is that 17 this drug did not work with the best possible 18 formulation in this population and, therefore, 19.....68 1 Secondly, an efficacy and safety dose did 2 not demonstrate a dose-response relationship in a 3 population of 253.....There you always get into the 5 issue of we don't know what kind of dose to use so 6 some sort of dose-ranging safety..
http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4050T1.DOC (score=24)

Guidance for Industry: Developing Medical Imaging Drug and Biological...
...administered at a mass dose that is at the low end of the dose-response curve, dose.....safety and effectiveness of the drug in humans, or if the radioactive drug has a.....that is lower than if the dose selection had been based on the results of acute, single..
http://www.fda.gov/cber/gdlns/medimagesaf.pdf (score=24)

Las Vegas Injury Lawyer